Conformational Dynamics of Sclerostin-LRP6 Complex Analyzed by HDX-MS |
Jeong, Yejing
(School of Pharmacy, Sungkyunkwan University)
Kim, Jinuk (Department of Biological Sciences, Seoul National University) Choi, Hee-Jung (Department of Biological Sciences, Seoul National University) Chung, Ka Young (School of Pharmacy, Sungkyunkwan University) |
1 | Semenov, M., Tamai, K. and He, X. (2005) SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem. 280, 26770-26775. DOI |
2 | Nolan, K., Kattamuri, C., Luedeke, D. M., Deng, X., Jagpal, A., Zhang, F., Linhardt, R. J., Kenny, A. P., Zorn, A. M. and Thompson, T. B. (2013) Structure of protein related to Dan and Cerberus: insights into the mechanism of bone morphogenetic protein antagonism. Structure 21, 1417-1429. DOI |
3 | Cheng, Z., Biechele, T., Wei, Z., Morrone, S., Moon, R. T., Wang, L. and Xu, W. (2011) Crystal structures of the extracellular domain of LRP6 and its complex with DKK1. Nat. Struct. Mol. Biol. 18, 1204-1210. DOI |
4 | Lintern, K. B., Guidato, S., Rowe, A., Saldanha, J. W. and Itasaki, N. (2009) Characterization of wise protein and its molecular mechanism to interact with both Wnt and BMP signals. J. Biol. Chem. 284, 23159-23168. DOI |
5 | Bourhis, E., Wang, W., Tam, C., Hwang, J., Zhang, Y., Spittler, D., Huang, O. W., Gong, Y., Estevez, A., Zilberleyb, I., Rouge, L., Chiu, C., Wu, Y., Costa, M., Hannoush, R. N., Franke, Y. and Cochran, A. G. (2011) Wnt antagonists bind through a short peptide to the first beta-propeller domain of LRP5/6. Structure 19, 1433-1442. DOI |
6 | Veverka, V., Henry, A. J., Slocombe, P. M., Ventom, A., Mulloy, B., Muskett, F. W., Muzylak, M., Greenslade, K., Moore, A., Zhang, L., Gong, J., Qian, X., Paszty, C., Taylor, R. J., Robinson, M. K. and Carr, M. D. (2009) Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J. Biol. Chem. 284, 10890-10900. DOI |
7 | Winkler, D. G., Sutherland, M. K., Geoghegan, J. C., Yu, C., Hayes, T., Skonier, J. E., Shpektor, D., Jonas, M., Kovacevich, B. R., Staehling-Hampton, K., Appleby, M., Brunkow, M. E. and Latham, J. A. (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 22, 6267-6276. DOI |
8 | Semenov, M. V. and He, X. (2006) LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J. Biol. Chem. 281, 38276-38284. DOI |
9 | Ahn, V. E., Chu, M. L., Choi, H. J., Tran, D., Abo, A. and Weis, W. I. (2011) Structural basis of Wnt signaling inhibition by Dickkopf binding to LRP5/6. Dev. Cell 21, 862-873. DOI |
10 | Balemans, W., Ebeling, M., Patel, N., Van Hul, E., Olson, P., Dioszegi, M., Lacza, C., Wuyts, W., Van Den Ende, J., Willems, P., PaesAlves, A. F., Hill, S., Bueno, M., Ramos, F. J., Tacconi, P., Dikkers, F. G., Stratakis, C., Lindpaintner, K., Vickery, B., Foernzler, D. and Van Hul, W. (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 10, 537-543. DOI |
11 | MacNabb, C., Patton, D. and Hayes, J. S. (2016) Sclerostin antibody therapy for the treatment of osteoporosis: clinical prospects and challenges. J. Osteoporos. 2016, 6217286. |
12 | DeBruine, Z. J., Xu, H. E. and Melcher, K. (2017) Assembly and architecture of the Wnt/beta-catenin signalosome at the membrane. Br. J. Pharmacol. 174, 4564-4574. DOI |
13 | Giladi, M., Lee, S. Y., Hiller, R., Chung, K. Y. and Khananshvili, D. (2015) Structure-dynamic determinants governing a mode of regulatory response and propagation of allosteric signal in splice variants of Na+/Ca2+ exchange (NCX) proteins. Biochem. J. 465, 489-501. DOI |
14 | Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y., Alisch, R. S., Gillett, L., Colbert, T., Tacconi, P., Galas, D., Hamersma, H., Beighton, P. and Mulligan, J. (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68, 577-589. DOI |
15 | Bourhis, E., Tam, C., Franke, Y., Bazan, J. F., Ernst, J., Hwang, J., Costa, M., Cochran, A. G. and Hannoush, R. N. (2010) Reconstitution of a frizzled8.Wnt3a.LRP6 signaling complex reveals multiple Wnt and Dkk1 binding sites on LRP6. J. Biol. Chem. 285, 9172-9179. DOI |
16 | Lewiecki, E. M. (2011) Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. Expert Opin. Biol. Ther. 11, 117-127. DOI |
17 | Holdsworth, G., Slocombe, P., Doyle, C., Sweeney, B., Veverka, V., Le Riche, K., Franklin, R. J., Compson, J., Brookings, D., Turner, J., Kennedy, J., Garlish, R., Shi, J., Newnham, L., McMillan, D., Muzylak, M., Carr, M. D., Henry, A. J., Ceska, T. and Robinson, M. K. (2012) Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors. J. Biol. Chem. 287, 26464-26477. DOI |
18 | Kim, J., Han, W., Park, T., Kim, E. J., Bang, I., Lee, H. S., Jeong, Y., Roh, K., Kim, J., Kim, J. S., Kang, C., Seok, C., Han, J. K., Choi, H. J. (2020) Sclerostin inhibits Wnt signaling through tandem interaction with two LRP6 ectodomains. Nat. Commun. 11, 5357. DOI |
19 | Li, X., Ominsky, M. S., Niu, Q. T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., Asuncion, F., Barrero, M., Warmington, K., Dwyer, D., Stolina, M., Morony, S., Sarosi, I., Kostenuik, P. J., Lacey, D. L., Simonet, W. S., Ke, H. Z. and Paszty, C. (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res. 23, 860-869. DOI |